Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

Anderson B Collier 3rd; Mark D Krailo; Ha M Dang; Steven G DuBois; Douglas S Hawkins; Mark L Bernstein; Lisa R Bomgaars; Damon R Reed; Richard G Gorlick; Katherine A Janeway

doi:10.1002/pbc.29333

Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

Pediatr Blood Cancer. 2021 Dec;68(12):e29333. doi: 10.1002/pbc.29333. Epub 2021 Sep 8.

Authors

Affiliations

¹ Department of Pediatrics, University of Mississippi Medical Center, Jackson, Mississippi, USA.
² Department of Preventive Medicine, University of Southern California, Los Angeles, California, USA.
³ Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, Massachusetts, USA.
⁴ Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington, USA.
⁵ IWK Health Centre, Dalhousie University, Port Williams, Nova Scotia, Canada.
⁶ Department of Pediatrics, Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, USA.
⁷ Cancer Center and Blood Disorders Institute, Johns Hopkins All Children's Hospital, St. Petersburg, Florida, USA and Department of Individualized Cancer Management, Moffitt Cancer Center, Tampa, Florida, USA.
⁸ MD Anderson Cancer Center, University of Texas, Houston, Texas, USA.

Abstract

SevenChildren's Oncology Group phase 2 trials for patients with relapsed/progressive solid tumors were analyzed to estimate the event-free survival (EFS) for relapsed/progressive Ewing sarcoma. One hundred twenty-eight Ewing sarcoma patients were enrolled and 124 events occurred. The 6-month EFS was 12.7%, demonstrating the poor outcome of these patients. Only docetaxel achieved its protocol-specified radiographic response rate for activity; however, the EFS for docetaxel was similar to other agents, indicating that a higher radiographic response rate may not translate into superior disease control. This EFS benchmark could be utilized as an additional endpoint in trials for recurrent Ewing sarcoma.

Keywords: Ewing sarcoma; event-free survival; objective response; outcome; phase 2 trials; relapsed.

Publication types

Clinical Trial, Phase II
Research Support, N.I.H., Extramural

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Bone Neoplasms* / pathology
Child
Docetaxel / therapeutic use
Humans
Neoplasm Recurrence, Local / drug therapy
Neuroectodermal Tumors, Primitive, Peripheral*
Sarcoma, Ewing* / pathology

Outcome of patients with relapsed or progressive Ewing sarcoma enrolled on cooperative group phase 2 clinical trials: A report from the Children's Oncology Group

Authors

Affiliations

Abstract

Publication types

MeSH terms

Substances

Supplementary concepts

Grants and funding